Skye Bioscience, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SKYE | MTVA | CANF | CMMB | QNTM | ENVB | |
|---|---|---|---|---|---|---|
| Market cap | 5.05M | 8.83M | 5.06M | 9.90M | 14.21M | 6.53M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.2 | — | -1.8 | -41.0 | -0.3 | -1.0 |
| Price/book | -10.1 | 1.3 | 0.7 | 1.0 | 2.1 | 0.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −90.63% | −85.67% | −80.12% | −52.33% | −74.27% | −75.83% |
| Today | −6.56% | +6.35% | −0.04% | +4.24% | 0.00% | −2.67% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SKYE news ›Skye Bioscience (NASDAQ:SKYE) Stock Price Up 1.3% – Still a Buy?
Posted by Tristan Rich on Oct 17th, 2026 Skye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report) shares were up 1.3% on Thursday. The company traded as high as $1.65 and last traded at $1.59. 17,470 shares traded hands during trading, a…
Pretax income of Skye Bioscience, Inc. – DUS:09R0
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.